Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial
July 23, 2021 16:21 ET
|
Protagenic Therapeutics, Inc.
NEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...
Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19
July 14, 2021 07:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral...
QSAM Biosciences Announces Submission of IND Application for CycloSam® with FDA
May 04, 2021 09:00 ET
|
QSAM Biosciences Inc.
Austin, TX, May 04, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases, announced...
Cancer Genetics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
November 02, 2020 16:00 ET
|
Cancer Genetics, Inc.
Rutherford, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or “the Company”), a leader in drug discovery and preclinical oncology and immuno-oncology...
Apollomics, Inc. Receives China Investigational New Drug Approval for APL-106 to Initiate a Phase 3 Bridging Study in Acute Myeloid Leukemia
September 27, 2020 20:05 ET
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China, Sept. 27, 2020 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Protagenic Therapeutics Completes $2.0 Million Convertible Note Financing
September 08, 2020 12:10 ET
|
Protagenic Therapeutics, Inc.
Capital to be Used to Complete IND Filing and Commence Phase I/II Clinical Trial for Lead Clinical Compound PT00114 NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc....
Hoverink Biotechnologies, Inc., today announced that they have completed an application with the USPTO for KAIYADRU®. Hoverink Biotechnologies, Inc plans to develop and commercialize KAIYADRU®
November 09, 2018 18:42 ET
|
Hoverink Biotechnologies, Inc
Overview On September 26, 2018 We filed trademark applications covering: LOS ANGELES, CA, Nov. 09, 2018 (GLOBE NEWSWIRE) -- KAIYADRU® Pharmaceutical preparations, namely,...
TLC Reports Last Patient Last Visit (LPLV) in TLC599 Phase II Trial and FDA Clearance to Commence New Clinical Trials
July 09, 2018 15:01 ET
|
Taiwan Liposome Company, Ltd.
LPLV marks the final steps toward completion of TLC599 trial for osteoarthritis (OA) painPhase II topline results on-track for 2018 releaseSet to initiate enrollment of US Phase II pharmacokinetic...
AXIM Biotech Announces Successful Completion of Pre-IND Meeting with FDA on Comparable Product to Marinol; Green Light from FDA for IND Submission
December 12, 2017 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Dec. 12, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC:AXIM), a world leader in cannabinoid research and development, announced today that it has successfully completed a...
C3 Jian Obtains FDA Acceptance of Investigational New Drug Application
May 24, 2012 12:06 ET
|
C3 Jian, Inc.
LOS ANGELES, May 24, 2012 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a private company focused on providing improved oral healthcare, announced today that its Investigational New Drug Application (IND) for...